Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $105.00 price target on Nektar Therapeutics (NASDAQ: NKTR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
